Press Releases

Vertex Pharmaceuticals Announces Webcast of its Presentation at the Citigroup 2006 Healthcare Conference Cambridge, MA, February 23, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Citigroup 2006 Healthcare Conference in Washington, DC.

-Plasma HCV RNA levels are less than 10 IU/mL in 12 of 12 patients after 28 days of dosing with VX-950/peg-IFN/RBV in Phase II study-

- Clinical, Research and Financial Objectives Achieved -

Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research Cambridge, MA and Bethesda, MD, January 12, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.

—Product Candidates with Transformational Potential Highlighted—

-Product Candidates with Transformational Potential Highlighted-

--Median 5.5 log10 reduction in HCV RNA achieved in patients receiving VX-950 and peg-IFN in 14-day clinical study--

- Positive Data Presented at 45th Annual ICAAC -

- VX-409 is first in a new class of subtype selective ion channel modulators -

- VX-409 is first in a new class of subtype selective ion channel modulators -

FDA Grants Fast Track Designation to Vertex’s Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to

FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to

- Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -

- Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -

- Investigational New Drug Application Activated in the U.S. -

- Investigational New Drug Application Activated in the U.S. -

- Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -

- Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -

Vertex Announces Filing of IND in Support of VX-950 Phase II Development in the U.S.

Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Cambridge, MA, November 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday, November 11, 2005 at 9:00 a.m. EST.